What it sells
AI Diagnosis of Heart Disease
Business model breakdown
Buyer: who owns the budget?
Health system leaders: cardiovascular service line directors, imaging and IT/security procurement.
Trigger: what makes them buy now?
Undiagnosed cardiac amyloid and new reimbursement: CPT 0932T outpatient (~$313 national average) and Medicare NTAP up to $2,275 per inpatient stay effective Oct 1 2026.
Workflow: what inputs become what output?
Standard DICOM studies go in (on-premise VM or validated cloud), AI result returns into the study the cardiologist reads; go-live in about four weeks.
Economics: what it saves and how it charges
UnverifiedHospital is reimbursed separately for the AI analysis (CPT 0932T, NTAP), which funds the software license.
Distribution: how it reaches customers
Direct enterprise sales to health systems (Request a Demo / scoping call).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.